Faldaprevir

• CAS: 801283-95-4
• Catalog Number: ACM801283954
• Category: Inhibitors
• Molecular Weight: 869.83
• Molecular Formula: C40H49BrN6O9S
• Description: Faldaprevir, also known as BI-201335, is a potent NS3/NS4A protease inhibitor potentially for the treatment of HCV infection. Faldaprevir is known to inhibit P-glycoprotein, CYP3A4, and UDP-glucuronosyltransferase 1A1.
• Synonyms: Faldaprevir; BI-201335; BI 201335; BI201335
• IUPAC Name: (1R,2S)-1-((2S,4R)-4-((8-bromo-2-(2-isobutyramidothiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)pyrrolidine-2-carboxamido)-2-vinylcyclopropane-1-carboxylic acid
• Canonical SMILES: O=C([C@]1(NC([C@H]2N(C([C@@H](NC(OC3CCCC3)=O)C(C)(C)C)=O)C[C@H](OC4=CC(C5=CSC(NC(C(C)C)=O)=N5)=NC6=C(Br)C(OC)=CC=C46)C2)=O)[C@H](C=C)C1)O
• InChI: InChI=1S/C40H49BrN6O9S/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48)/t21-,23-,27+,32-,40-/m1/s1
• InChI Key: LLGDPTDZOVKFDU-XUHJSTDZSA-N
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Shelf Life: >2 years if stored properly
• Storage: Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
• Alternative CAS: 1215856-44-2 (sodium); 801283-95-4 (free acid)
• Biological Target: Faldaprevir inhibits P-glycoprotein, CYP3A4, and UDP-glucuronosyltransferase 1A1.
• Drug Formulation: This drug may be formulated in DMSO
• Elemental Analysis: C, 55.23; H, 5.68; Br, 9.19; N, 9.66; O, 16.55; S, 3.69
• Exact Mass: 868.2465
• HS Tariff Code: 2934.99.9001
• In Vitro Activity: Inhibition of protease activity by BI 201335 was evaluated using the full-length NS3 protein coexpressed with the 54-amino-acid cofactor NS4A (NS3-NS4A). BI 201335 showed a similar level of inhibitory potency against the NS3-NS4A proteases of HCV genotypes 4a, 5a, and 6a as it did against the two genotype 1 enzymes (≤5-fold difference), but it was somewhat less potent against enzymes from HCV genotypes 2a, 2b, and 3a (20, 50, and 190-fold, relative to genotype 1a). BI 201335 also had no significant activity against the human serine and cysteine proteases elastase and cathepsin B (CatB). In vitro liver microsome stability studies revealed low metabolic clearance of <19% of hepatic blood flow (Qh) in all species tested, including humans, with the ranking order monkey > human > dog ≈ rat. BI 201335 was highly bound to human plasma proteins (99.6%), as determined by equilibrium dialysis.; Reference: Antimicrob Agents Chemother. 2010 Nov;54(11):4611-8. https://pubmed.ncbi.nlm.nih.gov/20823284/
• In Vivo Activity: The metabolism, pharmacokinetics, excretion and tissue distribution of a hepatitis C NS3/NS4 protease inhibitor, faldaprevir, were studied in rats following a single 2 mg/kg intravenous or 10 mg/kg oral administration of [(14)C]-faldaprevir. Following intravenous dosing, the terminal elimination t1/2 of plasma radioactivity was 1.75 h (males) and 1.74 h (females). Corresponding AUC0-∞, CL and Vss were 1920 and 1900 ngEq · h/mL, 18.3 and 17.7 mL/min/kg and 2.32 and 2.12 mL/kg for males and females, respectively. n intact rats, ≥90.17% dose was recovered in feces and only ≤1.08% dose was recovered in urine for both iv and oral doses. In bile cannulated rats, 54.95, 34.32 and 0.27% dose was recovered in feces, bile and urine, respectively. It was found that glucuronidation plays a major role in the metabolism of faldaprevir with minimal Phase I metabolism.; Reference: Xenobiotica. 2014 Nov;44(11):1014-25. https://pubmed.ncbi.nlm.nih.gov/24831541/
• Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
• Stock Solution Storage: 0-4 °C for short term (days to weeks), or -20 °C for long term (months).